Jubilant Pharmova Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The United States Food & Drug Administration (USFDA) conducted an audit of the facility from 28 May to 6 June 2024. The US drug regulatorhas now determined the inspection classification of the facility as “Voluntary Action Indicated”.

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company.

Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses.

The company's consolidated net profit stood at Rs 482.10 crore in Q1 FY25, steeply higher than Rs 6.40 crore in Q1 FY24. Total income increased by 9.41% YoY to Rs 1,745.7 crore in Q1 FY25.

The counter hit an all time high of 1,060.15 in today’s intraday session.

Powered by Capital Market - Live News

Alembic Pharmaceuticals Ltd, Doms Industries Ltd, EPL Ltd, Anand Rathi Wealth Ltd are among the other stocks to see a surge in volumes on NSE today, 09 September 2024.

Jubilant Pharmova Ltd recorded volume of 48.53 lakh shares by 14:14 IST on NSE, a 13.39 times surge over two-week average daily volume of 3.63 lakh shares. The stock gained 9.59% to Rs.1,042.95. Volumes stood at 6.95 lakh shares in the last session.

Alembic Pharmaceuticals Ltd registered volume of 16.12 lakh shares by 14:14 IST on NSE, a 5.56 fold spurt over two-week average daily volume of 2.90 lakh shares. The stock rose 6.53% to Rs.1,177.90. Volumes stood at 3.88 lakh shares in the last session.

Doms Industries Ltd saw volume of 5.39 lakh shares by 14:14 IST on NSE, a 4.79 fold spurt over two-week average daily volume of 1.12 lakh shares. The stock increased 4.17% to Rs.2,739.45. Volumes stood at 71266 shares in the last session.

EPL Ltd recorded volume of 69.2 lakh shares by 14:14 IST on NSE, a 3.46 times surge over two-week average daily volume of 19.99 lakh shares. The stock gained 1.54% to Rs.258.74. Volumes stood at 12.37 lakh shares in the last session.

Anand Rathi Wealth Ltd saw volume of 1.37 lakh shares by 14:14 IST on NSE, a 3.33 fold spurt over two-week average daily volume of 41195 shares. The stock dropped 2.61% to Rs.3,817.00. Volumes stood at 38990 shares in the last session.

Powered by Capital Market - Live News

Morepen Laboratories Ltd, La Opala RG Ltd, AGI Greenpac Ltd and Gujarat Alkalies & Chemicals Ltd are among the other gainers in the BSE's 'A' group today, 09 September 2024.

Jubilant Pharmova Ltd soared 7.18% to Rs 1020.25 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 72950 shares were traded on the counter so far as against the average daily volumes of 27440 shares in the past one month.

Morepen Laboratories Ltd surged 6.90% to Rs 95.5. The stock was the second biggest gainer in 'A' group. On the BSE, 13.81 lakh shares were traded on the counter so far as against the average daily volumes of 33.4 lakh shares in the past one month.

La Opala RG Ltd spiked 5.76% to Rs 359.7. The stock was the third biggest gainer in 'A' group. On the BSE, 79605 shares were traded on the counter so far as against the average daily volumes of 11043 shares in the past one month.

AGI Greenpac Ltd gained 5.33% to Rs 947.75. The stock was the fourth biggest gainer in 'A' group. On the BSE, 33424 shares were traded on the counter so far as against the average daily volumes of 24883 shares in the past one month.

Gujarat Alkalies & Chemicals Ltd exploded 4.97% to Rs 822.2. The stock was the fifth biggest gainer in 'A' group. On the BSE, 29691 shares were traded on the counter so far as against the average daily volumes of 5923 shares in the past one month.

Powered by Capital Market - Live News

Jubilant Biosys Innovative Research Services,, Singapore (JBIRSPL), subsidiary of Jubilant Biosys (JBL), a wholly owned subsidiary of Jubilant Pharmova, has signed and issued a “put option offer” to Pierre Fabre Laboratories (PF), which setsforth an offer to acquire 80% equity capital (approx. Euro 4.4 million over a period of 2 years) in a new company to be incorporated in France, which new company shall acquire Pierre Fabre's R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France. 

The aforesaid contemplated collaboration is subject to prior consultation of the PF works council and approval of the offer by PF, as well as finalization of definitive agreements and customary closing conditions.

Post‐closing of the transaction: 

- New Company would utilize this R&D Centre with capability to collaborate with Big Pharma & Biotech Customers in Europe & USA.   

- This contemplated transaction would enable JBL to strengthen its drug discovery capabilities in the fields of biologics and antibody drug conjugates (ADC).   

- PF may invest 20% equity capital (approx. Euro 1.1 million over a period of 2 years) in a new company for a maximum period of 5 years, during which time they may continue to provide support to the new company to transition the R&D Centre into fully independent contract research organization, with PFG having no access to any proprietary information or IP related to the R&D Centre. 

- PF may also hire services from JBL aggregating to Euro 7 million for first 4 years

Powered by Capital Market - Live News